Agency Business briefs: February 2014

Share this article:
Yannick Bolloré
Yannick Bolloré

Havas announced that Yannick Bolloré (pictured), son of Vincent Bolloré, will become chief executive of the group. He replaces David Jones, who is stepping down after 15 years with the firm to co-found a tech startup. Andrew Benett, co-president, Havas Worldwide, has been promoted to CEO of the advertising network and will report to Yannick.

Fingerpaint Mar­keting, originally based out of Saratoga Springs, has expanded to New York City and deemed the new location—at 825 Third Avenue—its global headquarters. The location is Fingerpaint's fourth office, adding to offices in Albany and Wayne, PA.

FDA's former associate commissioner for the office of external affairs, Virginia Cox, has rejoined consulting group 3D Communications, where she previously worked. Cox has also worked at the Consumer Healthcare Products Association (CHPA).

Ogilvy CommonHealth Worldwide brought on Maggie Helmig as executive vice president, global brand lead at the network's Ogilvy Healthworld office in New York. She will head a client team as the global brand lead and be responsible for maintaining the agency's client relationships.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?